Hrtwr Intrntl Inc (HTWR) 57.96 $HTWR
Shares of HTWR Up 76.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 28, 12:41PM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 2 month, HeartWare International has returned 76.56% as of today's recent price of $57.86.
HTWR: 57.96 (+0.02)
HeartWare International Reports $68.7 Million In Second Quarter 2016 Revenue
PR Newswire - Thu Jul 28, 7:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced total revenue of $68.7 million for the quarter ended June 30, 2016, compared to $73.6 million for the same period in 2015 and $55.1 million for the first quarter of 2016. Total revenue decreased approximately 7% year-over-year, which is primarily attributable to the third quarter 2015 completion of enrollment of the company's ENDURANCE2 Destination Therapy (DT) clinical trial, which contributed approximately $5 million to revenue in the second quarter of 2015.
MDT: 88.06 (+0.43), HTWR: 57.96 (+0.02)
Healthcare Sector Equities Under Review -- Intrexon, Alkermes, BioScrip, and Heartware Intl.
PR Newswire - Tue Jul 26, 7:50AM CDT
The Healthcare sector presents some of the most profitable trades in the market, but challenges, such as ransom-ware risks, demand pressures, and cost issues, continue to persist. Today, Stock-Callers.com presents these four companies for further assessment: Intrexon Corp. (NYSE: XON), Alkermes PLC (NASDAQ: ALKS), BioScrip Inc. (NASDAQ: BIOS), and Heartware International Inc. (NASDAQ: HTWR). Learn more about these stocks by accessing their freenotes at:
XON: 27.38 (+2.05), BIOS: 2.58 (+0.02), HTWR: 57.96 (+0.02), ALKS: 49.56 (-0.34)
MedTech Tailwinds at a Glance: Which Stocks to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:02PM CDT
MedTech Tailwinds at a Glance: Which Stocks to Buy?
ABMD: 119.50 (+1.53), LDRH: 36.98 (-0.02), MDT: 88.06 (+0.43), PAHC: 20.83 (+0.20), MLAB: 114.10 (-1.53), NUVA: 63.29 (+1.09), BSX: 24.43 (+0.15), BABY: 39.18 (-0.15), SNN: 33.18 (-0.11), JNJ: 125.40 (+0.17), DXCM: 92.65 (+0.42), GWPH: 96.11 (+1.79), RMD: 69.85 (+0.97), WOOF: 70.40 (-0.94), ABT: 45.29 (+0.54), VIVO: 19.55 (+0.19), MASI: 52.93 (-0.04), TMO: 159.56 (+0.72), CYH: 12.58 (-0.19), HTWR: 57.96 (+0.02), FEIC: 106.45 (+0.03), ISRG: 693.87 (-1.89), CFMS: 6.92 (-0.05), STE: 71.41 (+0.46), STJ: 83.73 (+0.69), XRAY: 64.23 (+0.19), HOLX: 38.98 (+0.49)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), ZBH: 131.06 (-0.08), LDRH: 36.98 (-0.02), MDT: 88.06 (+0.43), TMO: 159.56 (+0.72), STJ: 83.73 (+0.69), HTWR: 57.96 (+0.02), XRAY: 64.23 (+0.19), NUVA: 63.29 (+1.09), FEIC: 106.45 (+0.03)
HeartWare Presentation At The Goldman Sachs 37th Annual Global Healthcare Conference To Be Webcast
PR Newswire - Wed Jun 01, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that members of HeartWare's executive management are scheduled to participate in a webcast session at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016 at 10:40 a.m. PT (1:40 p.m. ET). The conference is being held June 7-9 in Rancho Palos Verdes, California.
HTWR: 57.96 (+0.02)
HeartWare International Shares Down 16.8% Since SmarTrend's Sell Call (HTWR)
Comtex SmarTrend(R) - Fri May 20, 1:51PM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 16.84% as of today's recent price of $28.01.
HTWR: 57.96 (+0.02)
HeartWare International Has Returned 19.9% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Fri May 13, 1:03AM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 19.86% as of today's recent price of $27.00.
HTWR: 57.96 (+0.02)
HeartWare Presentation At The Bank Of America Merrill Lynch 2016 Health Care Conference To Be Webcast
PR Newswire - Thu May 05, 3:15PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 4:20 p.m. PT (7:20 p.m. ET). The conference is being held May 10-12 in Las Vegas.
HTWR: 57.96 (+0.02)
Why Heartware International's Shares Are Sinking 12% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:17AM CDT
SOURCE: HEARTWARE INTERNATIONAL, INC. What: After reporting first-quarter financial results that fell shy of industry watchers' forecasts, shares of Heartware International were tumbling by 12.4% at 11:30 a.m. EST. So what: The maker of...
HTWR: 57.96 (+0.02)
HeartWare International Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 6:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue derived from HeartWare® Ventricular Assist System (HVAD® System) sales of $55.1 million for the first quarter ended March 31, 2016, compared to $70.0 million in revenue for the same period in 2015.
HTWR: 57.96 (+0.02)
HeartWare Completes Enrollment In HVAD® System LATERAL Study(TM)
PR Newswire - Wed Apr 27, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced completion of enrollment in the HeartWare® Ventricular Assist System (HVAD® System) LATERAL Study(TM).
HTWR: 57.96 (+0.02)
HeartWare Announces HVAD® System Scientific Presentations At The International Society For Heart And Lung Transplantation 36th Annual Meeting
PR Newswire - Wed Apr 20, 8:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced a series of scientific presentations, highlighting the clinical and commercial use of the HVAD® System, at the International Society for Heart and Lung Transplantation (ISHLT) 36th Annual Meeting and Scientific Sessions to be held at the Marriott Wardman Park Hotel in Washington, D.C. on April 27-30, 2016.
HTWR: 57.96 (+0.02)
HeartWare Schedules First Quarter 2016 Financial Results Conference Call And Webcast
PR Newswire - Tue Apr 19, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call and webcast to discuss its financial results for the three months ended March 31, 2016, on Wednesday, May 4, 2016 at 8:00 a.m. ET. The company plans to release the financial results prior to the conference call and webcast, during which management will discuss the company's financial results, highlights from the first quarter and business outlook.
HTWR: 57.96 (+0.02)
Ventricular Assist Device Market Analysis - Key Players are Abiomed, HeartWare International & Berlin Heart - Research and Markets
BusinessWire - Wed Mar 30, 7:37AM CDT
Research and Markets has announced the addition of the "Ventricular Assist Device Market Analysis by Product (Left, Right, Bi- Ventricular Assist Devices), and Segment Forecasts To 2022" report to their offering.
HTWR: 57.96 (+0.02)
March 22 Deadline Alert: Law Offices of Howard G. Smith Reminds HeartWare International, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Mon Mar 21, 10:56AM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming March 22, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased HeartWare International, Inc. ("HeartWare" or the "Company"
(Nasdaq: HTWR) securities between June 10, 2014 and January 11, 2016, inclusive (the "Class Period". Investors who suffered losses on their investment in HeartWare securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
HTWR: 57.96 (+0.02)
INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving HeartWare International, Inc. and a Lead Plaintiff Deadline of March 22, 2016 - HTWR
GlobeNewswire - Mon Mar 21, 10:48AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased HeartWare International, Inc. (Nasdaq:HTWR) securities between June 10, 2014 and January 11, 2016.
HTWR: 57.96 (+0.02)
HEARTWARE 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against HeartWare International Inc. - HTWR
GlobeNewswire - Fri Mar 18, 9:03PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 22, 2016 to file lead plaintiff applications in a securities class action lawsuit against HeartWare International Inc. (Nasdaq:HTWR). Investor losses must relate to purchases of the Company's securities between June 10, 2014 and January 11, 2016. This action is pending in the United States District Court for the Southern District of New York.
HTWR: 57.96 (+0.02)
SHAREHOLDER NOTICE: Rosen Law Firm Reminds HeartWare International Inc. Investors of Important March 22, 2016 Deadline in Class Action -- HTWR
GlobeNewswire - Fri Mar 18, 5:22PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of HeartWare International Inc. securities (NASDAQ:HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the "Class Period" of the important March 22, 2016 lead plaintiff deadline. The lawsuit seeks to recover damages for HeartWare investors under the federal securities laws.
HTWR: 57.96 (+0.02)
March 22 Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against HeartWare International, Inc.
BusinessWire - Thu Mar 17, 11:36AM CDT
Glancy Prongay & Murray LLP ("GPM" reminds investors of the upcoming March 22, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class" of investors who purchased HeartWare International, Inc. ("HeartWare" or the "Company" (NASDAQ: HTWR) securities between June 10, 2014 and January 11, 2016, inclusive (the "Class Period". Long term HeartWare investors, who are holding their HeartWare shares, are encouraged to contact GPM to discuss their legal rights.
HTWR: 57.96 (+0.02)
Shares of HTWR Up 76.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jul 28, 12:41PM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on June 13th, 2016 at $32.77. In approximately 2 month, HeartWare International has returned 76.56% as of today's recent price of $57.86.
HTWR: 57.96 (+0.02)
HeartWare International Reports $68.7 Million In Second Quarter 2016 Revenue
PR Newswire - Thu Jul 28, 7:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced total revenue of $68.7 million for the quarter ended June 30, 2016, compared to $73.6 million for the same period in 2015 and $55.1 million for the first quarter of 2016. Total revenue decreased approximately 7% year-over-year, which is primarily attributable to the third quarter 2015 completion of enrollment of the company's ENDURANCE2 Destination Therapy (DT) clinical trial, which contributed approximately $5 million to revenue in the second quarter of 2015.
MDT: 88.06 (+0.43), HTWR: 57.96 (+0.02)
Healthcare Sector Equities Under Review -- Intrexon, Alkermes, BioScrip, and Heartware Intl.
PR Newswire - Tue Jul 26, 7:50AM CDT
The Healthcare sector presents some of the most profitable trades in the market, but challenges, such as ransom-ware risks, demand pressures, and cost issues, continue to persist. Today, Stock-Callers.com presents these four companies for further assessment: Intrexon Corp. (NYSE: XON), Alkermes PLC (NASDAQ: ALKS), BioScrip Inc. (NASDAQ: BIOS), and Heartware International Inc. (NASDAQ: HTWR). Learn more about these stocks by accessing their freenotes at:
XON: 27.38 (+2.05), BIOS: 2.58 (+0.02), HTWR: 57.96 (+0.02), ALKS: 49.56 (-0.34)
MedTech Tailwinds at a Glance: Which Stocks to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 5:02PM CDT
MedTech Tailwinds at a Glance: Which Stocks to Buy?
ABMD: 119.50 (+1.53), LDRH: 36.98 (-0.02), MDT: 88.06 (+0.43), PAHC: 20.83 (+0.20), MLAB: 114.10 (-1.53), NUVA: 63.29 (+1.09), BSX: 24.43 (+0.15), BABY: 39.18 (-0.15), SNN: 33.18 (-0.11), JNJ: 125.40 (+0.17), DXCM: 92.65 (+0.42), GWPH: 96.11 (+1.79), RMD: 69.85 (+0.97), WOOF: 70.40 (-0.94), ABT: 45.29 (+0.54), VIVO: 19.55 (+0.19), MASI: 52.93 (-0.04), TMO: 159.56 (+0.72), CYH: 12.58 (-0.19), HTWR: 57.96 (+0.02), FEIC: 106.45 (+0.03), ISRG: 693.87 (-1.89), CFMS: 6.92 (-0.05), STE: 71.41 (+0.46), STJ: 83.73 (+0.69), XRAY: 64.23 (+0.19), HOLX: 38.98 (+0.49)
Medical Device Consolidation Frenzy: Here's How to Play it
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:00AM CDT
The medical device majors struggling with their core businesses are often on the lookout for emerging therapies through acquisitions and alliances.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), ZBH: 131.06 (-0.08), LDRH: 36.98 (-0.02), MDT: 88.06 (+0.43), TMO: 159.56 (+0.72), STJ: 83.73 (+0.69), HTWR: 57.96 (+0.02), XRAY: 64.23 (+0.19), NUVA: 63.29 (+1.09), FEIC: 106.45 (+0.03)
HeartWare Presentation At The Goldman Sachs 37th Annual Global Healthcare Conference To Be Webcast
PR Newswire - Wed Jun 01, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that members of HeartWare's executive management are scheduled to participate in a webcast session at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016 at 10:40 a.m. PT (1:40 p.m. ET). The conference is being held June 7-9 in Rancho Palos Verdes, California.
HTWR: 57.96 (+0.02)
HeartWare International Shares Down 16.8% Since SmarTrend's Sell Call (HTWR)
Comtex SmarTrend(R) - Fri May 20, 1:51PM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 16.84% as of today's recent price of $28.01.
HTWR: 57.96 (+0.02)
HeartWare International Has Returned 19.9% Since SmarTrend Recommendation (HTWR)
Comtex SmarTrend(R) - Fri May 13, 1:03AM CDT
SmarTrend identified a Downtrend for HeartWare International (NASDAQ:HTWR) on February 11th, 2016 at $33.69. In approximately 3 months, HeartWare International has returned 19.86% as of today's recent price of $27.00.
HTWR: 57.96 (+0.02)
HeartWare Presentation At The Bank Of America Merrill Lynch 2016 Health Care Conference To Be Webcast
PR Newswire - Thu May 05, 3:15PM CDT
HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that President and Chief Executive Officer Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 4:20 p.m. PT (7:20 p.m. ET). The conference is being held May 10-12 in Las Vegas.
HTWR: 57.96 (+0.02)
Why Heartware International's Shares Are Sinking 12% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:17AM CDT
SOURCE: HEARTWARE INTERNATIONAL, INC. What: After reporting first-quarter financial results that fell shy of industry watchers' forecasts, shares of Heartware International were tumbling by 12.4% at 11:30 a.m. EST. So what: The maker of...
HTWR: 57.96 (+0.02)
HeartWare International Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 6:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue derived from HeartWare® Ventricular Assist System (HVAD® System) sales of $55.1 million for the first quarter ended March 31, 2016, compared to $70.0 million in revenue for the same period in 2015.
HTWR: 57.96 (+0.02)
HeartWare Completes Enrollment In HVAD® System LATERAL Study(TM)
PR Newswire - Wed Apr 27, 3:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced completion of enrollment in the HeartWare® Ventricular Assist System (HVAD® System) LATERAL Study(TM).
HTWR: 57.96 (+0.02)
HeartWare Announces HVAD® System Scientific Presentations At The International Society For Heart And Lung Transplantation 36th Annual Meeting
PR Newswire - Wed Apr 20, 8:00AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced a series of scientific presentations, highlighting the clinical and commercial use of the HVAD® System, at the International Society for Heart and Lung Transplantation (ISHLT) 36th Annual Meeting and Scientific Sessions to be held at the Marriott Wardman Park Hotel in Washington, D.C. on April 27-30, 2016.
HTWR: 57.96 (+0.02)
HeartWare Schedules First Quarter 2016 Financial Results Conference Call And Webcast
PR Newswire - Tue Apr 19, 3:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call and webcast to discuss its financial results for the three months ended March 31, 2016, on Wednesday, May 4, 2016 at 8:00 a.m. ET. The company plans to release the financial results prior to the conference call and webcast, during which management will discuss the company's financial results, highlights from the first quarter and business outlook.
HTWR: 57.96 (+0.02)
Ventricular Assist Device Market Analysis - Key Players are Abiomed, HeartWare International & Berlin Heart - Research and Markets
BusinessWire - Wed Mar 30, 7:37AM CDT
Research and Markets has announced the addition of the "Ventricular Assist Device Market Analysis by Product (Left, Right, Bi- Ventricular Assist Devices), and Segment Forecasts To 2022" report to their offering.
HTWR: 57.96 (+0.02)
March 22 Deadline Alert: Law Offices of Howard G. Smith Reminds HeartWare International, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Mon Mar 21, 10:56AM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming March 22, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased HeartWare International, Inc. ("HeartWare" or the "Company"
(Nasdaq: HTWR) securities between June 10, 2014 and January 11, 2016, inclusive (the "Class Period". Investors who suffered losses on their investment in HeartWare securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights. HTWR: 57.96 (+0.02)
INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving HeartWare International, Inc. and a Lead Plaintiff Deadline of March 22, 2016 - HTWR
GlobeNewswire - Mon Mar 21, 10:48AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased HeartWare International, Inc. (Nasdaq:HTWR) securities between June 10, 2014 and January 11, 2016.
HTWR: 57.96 (+0.02)
HEARTWARE 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against HeartWare International Inc. - HTWR
GlobeNewswire - Fri Mar 18, 9:03PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 22, 2016 to file lead plaintiff applications in a securities class action lawsuit against HeartWare International Inc. (Nasdaq:HTWR). Investor losses must relate to purchases of the Company's securities between June 10, 2014 and January 11, 2016. This action is pending in the United States District Court for the Southern District of New York. HTWR: 57.96 (+0.02)
SHAREHOLDER NOTICE: Rosen Law Firm Reminds HeartWare International Inc. Investors of Important March 22, 2016 Deadline in Class Action -- HTWR
GlobeNewswire - Fri Mar 18, 5:22PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of HeartWare International Inc. securities (NASDAQ:HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the "Class Period"
of the important March 22, 2016 lead plaintiff deadline. The lawsuit seeks to recover damages for HeartWare investors under the federal securities laws. HTWR: 57.96 (+0.02)
March 22 Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against HeartWare International, Inc.
BusinessWire - Thu Mar 17, 11:36AM CDT
Glancy Prongay & Murray LLP ("GPM"
reminds investors of the upcoming March 22, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class" of investors who purchased HeartWare International, Inc. ("HeartWare" or the "Company" (NASDAQ: HTWR) securities between June 10, 2014 and January 11, 2016, inclusive (the "Class Period". Long term HeartWare investors, who are holding their HeartWare shares, are encouraged to contact GPM to discuss their legal rights. HTWR: 57.96 (+0.02)
